Phaseline

Targets › PTEN

PTEN (Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.

Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. (UniProt, P60484)

Open in Phaseline: the race on PTEN, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenPegloticase
Recombinant uricase enzyme that catalyzes degradation of uric acid
PTENPhase 3Uncontrolled GoutJun 2028
PharosgenMPD-1
Doxorubicin prodrug targeting KRAS mutant/PTEN loss advanced cancer
KRAS, PTENPhase 1CancerDec 2026

Conditions

Cancer (1) Uncontrolled Gout (1)

Modalities

small molecule (1), mixed (1)

Companies

Pharosgen (1) Amgen (1)

Related targets

KRAS (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.